Telma H 80 mg Tablet

Telma H 80mg tablet is a combination antihypertensive medication used to manage high blood pressure (hypertension).It contains two active ingredient Telmisartan in (80mg) concentration and Hydrochlorothiazide (12.5mg) concentration.

Medicine work together to help relax blood vessels, making it easier for blood to flow and lowering blood pressure. Always follow doctor's prescription as recommended to administer the dosage correctly and duration of the medication.

Manage blood pressure

Telma H 80mg tablet cause acute or mild symptoms that harm the body in many ways. Always visit the doctor if any of the side effects appear:

• Fatigue
  
• Bradycardia
  
• Gastrointestinal disturbance
  
• Electrolyte imbalance
  
• Postural hypotension
  
• Angioedema and urticaria
  
• Visual disturbance
  
• Breathlessness
  
• Muscle cramp
  
• Headache
  
• Dizziness
  
• Sleepiness
  
• Ankle swelling
  

• Telma H 80mg tablet taken with or without food by consulting to a healthcare provider.
• Do not overdose the medication to make up for the missed one, just take the next dose on the scheduled time.
• Always follow prescribed dosage and duration as administered by the healthcare professional.
  

• Telma 80mg tablet is an angiotensin II receptor blocker (ARB), a type of antihypertensive medication.
• It contains two active ingredients that help lower blood pressure.
• It works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow.
• By doing so, it allows blood vessels to relax and widen, reducing blood pressure, improving heart function, and making it easier for the heart to pump blood.

• Deppeler, H. P. (1981). Hydrochlorothiazide. In Analytical profiles of drug substances (Vol. 10, pp. 405-441). Academic Press.
  
• Herman, L. L., Weber, P., & Bashir, K. (2023). Hydrochlorothiazide. In StatPearls [Internet]. StatPearls Publishing.
  
• Beermann, B., & Groschinsky-Grind, M. (1977). Pharmacokinetics of hydrochlorothiazide in man. European Journal of Clinical Pharmacology, 12(4), 297-303.
  
• Mann, J. F., Schmieder, R. E., Dyal, L., McQueen, M. J., Schumacher, H., Pogue, J., ... & TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. (2009). Effect of telmisartan on renal outcomes: a randomized trial. Annals of internal medicine, 151(1), 1-10.
  
• Ontarget Investigators. (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine, 358(15), 1547-1559.​